4-(2-氨基-2-甲基丙基)苯胺 | 51131-55-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(2-氨基-2-甲基丙基)苯胺
• 英文名称: 4-(β-amino-isobutyl)-aniline
• 英文别名: 2-Amino-2-methyl-1-(4-amino-phenyl)-propan；4-(β-Amino-isobutyl)-anilin；2-Amino-2-methyl-1-(4-aminophenyl)propane；2-(4-aminophenyl)-1,1-dimethylethylamine；4-(2-amino-2-methyl-propyl)-phenylamine；4-(2-amino-2-methylpropyl)phenylamine；4-(2-Amino-2-methylpropyl)aniline
• CAS: 51131-55-6
• 化学式: C₁₀H₁₆N₂
• 分子量: 164.25
• InChiKey: GVKXPMXVIMAJIV-UHFFFAOYSA-N

物化性质

• 熔点：
  81-82 °C
• 沸点：
  288.8±15.0 °C(Predicted)
• 密度：
  1.018±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  52
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(2-氨基-2-甲基丙基)苯胺 在 硫酸 、 sodium iodide 、 sodium nitrite 作用下， 生成 2-amino-2-methyl-1-(4-iodophenyl)propane
  参考文献：
  名称：

  Carbostyril derivatives having potent .beta.-adrenergic agonist properties

  摘要：

  Derivatives carrying a substituent in the para position of the phenyl group of 8-hydroxy-5-[2-[(1-phenyl-2-methylprop-2-yl)amino]-1-hydroxyethyl] carbostyril (10) were prepared and their effects on beta-adrenoceptors evaluated in vitro. Unsubstituted compound 10, iodo 11, amino 12, and bromoacetamido 13 derivatives (all racemic) bound to the receptor with 15-100-fold lower dissociation constants than that of (-)-isoproterenol. All the above compounds stimulated adenylate cyclase more potently than (-)-isoproterenol. The intrinsic activities of compounds 10 and 12 were equal to that of (-)-isoproterenol. The intrinsic activities of compounds 11 and 13 were 1.3 and 1.2 times that of (-)-isoproterenol, respectively. Treatment of membrane preparations with bromoacetamido derivative 13 resulted in an irreversible loss of binding sites, and thus, 13 seems to be an alkylating affinity label for beta-adrenoceptors.

  DOI：

  10.1021/jm00392a006
• 作为产物：
  描述：

  盐酸苯丁胺 在 sodium hydroxide 、 硫酸 、 硝酸 、 镍 、 肼 作用下， 以 乙醇 为溶剂， 反应 0.66h， 生成 4-(2-氨基-2-甲基丙基)苯胺
  参考文献：
  名称：

  Carbostyril derivatives having potent .beta.-adrenergic agonist properties

  摘要：

  Derivatives carrying a substituent in the para position of the phenyl group of 8-hydroxy-5-[2-[(1-phenyl-2-methylprop-2-yl)amino]-1-hydroxyethyl] carbostyril (10) were prepared and their effects on beta-adrenoceptors evaluated in vitro. Unsubstituted compound 10, iodo 11, amino 12, and bromoacetamido 13 derivatives (all racemic) bound to the receptor with 15-100-fold lower dissociation constants than that of (-)-isoproterenol. All the above compounds stimulated adenylate cyclase more potently than (-)-isoproterenol. The intrinsic activities of compounds 10 and 12 were equal to that of (-)-isoproterenol. The intrinsic activities of compounds 11 and 13 were 1.3 and 1.2 times that of (-)-isoproterenol, respectively. Treatment of membrane preparations with bromoacetamido derivative 13 resulted in an irreversible loss of binding sites, and thus, 13 seems to be an alkylating affinity label for beta-adrenoceptors.

  DOI：

  10.1021/jm00392a006

文献信息

• [EN] CCR10 ANTAGONISTS<br/>[FR] ANTAGONISTES DE CCR10
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2009052078A1

  公开（公告）日：2009-04-23

  The invention relates to a compound of formula (I) or a tautomer thereof or a pharmaceutically acceptable salt thereof, wherein R1 to R11, W, X, Y, Z, and n are as defined herein. The invention also relates to methods of using the compounds of formula (I) and compositions thereof to treat various diseases and disorders in a patient. The invention also relates to processes for preparing the compounds of formula (I) and intermediates useful in these processes.

  该发明涉及公式（I）的化合物或其互变异构体或其药学上可接受的盐，其中R1至R11，W，X，Y，Z和n如本文所定义。该发明还涉及使用公式（I）的化合物及其组合物治疗患者的各种疾病和障碍的方法。该发明还涉及制备公式（I）化合物和在这些过程中有用的中间体的方法。
• Substituted sulfonamides as selective .beta..sub.3 agonists for the
  申请人：Merck & Co., Inc.

  公开号：US05541197A1

  公开（公告）日：1996-07-30

  Substituted sulfonamides are selective .beta..sub.3 adrenergic receptor agonists with very little .beta..sub.1 and .beta..sub.2 adrenergic receptor activity and as such the compounds are capable of increasing lipolysis and energy expenditure in cells. The compounds thus have potent activity in the treatment of Type II diabetes and obesity. The compounds can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compounds can be used to reduced neurogenic inflammation or as antidepressant agents. The compounds are prepared by coupling an aminoalkylphenyl-sulfonamide with an appropriately substituted epoxide. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for increasing gut motility are also disclosed.

  磺胺替代物是选择性的β3肾上腺素受体激动剂，几乎没有β1和β2肾上腺素受体活性，因此这些化合物能够增加细胞内的脂解和能量消耗。这些化合物在治疗2型糖尿病和肥胖症方面具有强效活性。这些化合物还可用于降低甘油三酯水平和胆固醇水平，或提高高密度脂蛋白水平，或减少肠道蠕动。此外，这些化合物可用于减少神经源性炎症或作为抗抑郁药物。这些化合物是通过将氨基烷基苯磺胺与适当取代的环氧化物偶联而制备的。还公开了用于治疗糖尿病和肥胖症以及降低甘油三酯水平和胆固醇水平或提高高密度脂蛋白水平或增加肠道蠕动的化合物的组合物和方法。
• Synthesis and Adrenergic Activity of a New Series of <i>N</i>-Aryl Dicyclopropyl Ketone Oxime Ethers: SAR and Stereochemical Aspects
  作者：Madeleine Blanc、Abderrafii Tamir、Silvère Aubriot、Marie Claude Michel、Mohamed Bouzoubaa、Gérard Leclerc、Pierre Demenge

  DOI：10.1021/jm970338c

  日期：1998.5.1

  A novel series of 31 N-aryl dicyclopropyl ketone oxime ethers were synthesized and tested for their activity at alpha- and beta-adrenergic receptors. All of the compounds showed greater affinity for beta-than for alpha1-receptor sites. Some compounds had pure antagonist effects whereas some were partial agonists. Several compounds had an antagonist effect matching that of propranolol in in vitro (binding

  合成了一系列新颖的31种N-芳基二环丙基酮肟醚，并测试了它们在α-和β-肾上腺素能受体上的活性。所有这些化合物对β的亲和力都比对α1受体的更大。一些化合物具有纯的拮抗作用，而另一些则是部分激动剂。几种化合物在体外（在大鼠心室匀浆和豚鼠上的结合数据和pA2值分别自发地击败右和电驱动的左心房分离制剂）具有与普萘洛尔相当的拮抗作用，并且在体内试验中（拮抗对异丙肾上腺素诱导的麻醉性大鼠心动过速）。此外，所有化合物均显示出β1肾上腺素选择性（β2亲和力> 1500 nM）。
• Beta-agonist carbostyril derivatives, assay method and pharmacological
  申请人：University of Florida

  公开号：US04894219A1

  公开（公告）日：1990-01-16

  Beta-agonist carbostyril derivatives having the formula ##STR1## wherein X may be the ortho, meta or para position and is selected from the group consisting of halogen, amino and substituted and unsubstituted lower alkanoylamino having from 1 to 6 carbon atoms and pharmaceutically acceptable salts and complexes thereof.

  具有以下公式的β-激动剂卡波斯蒂尔衍生物 ##STR1## 其中X可以是邻位、间位或对位，选择自卤素、氨基和取代和未取代的含有1至6个碳原子的低级烷酰胺基团以及其药用盐和络合物。
• Novel long acting bronchodilators for the treatment of respiratory diseases
  申请人：Grauert Matthias

  公开号：US20050256114A1

  公开（公告）日：2005-11-17

  The invention relates to compounds of general formula 1 wherein n, A, B, D, L, R 1 , R 2 , R 3 and R 4 may have the meanings given in the claims and in the specification, processes for preparing them, and their use as pharmaceutical compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints.

  该发明涉及一般式1的化合物，其中n、A、B、D、L、R1、R2、R3和R4可以具有索赔和规范中给定的含义，以及制备它们的过程，以及它们作为药物组合物的用途，特别是作为用于治疗呼吸道疾病的药物组合物。